3种甘草酸制剂治疗抗结核药物肝损伤的成本-效果比较OA

OBJECTIVE:To evaluate the cost-effectiveness of magnesium isoglycyrrhizinate,glycyrrhizin ammonium cysteine and compound ammonium glycyrrhizin S in the treatment of anti-tuberculosis drug induced liver injury,and to provide theoretical reference for the rational selection of glycyrrhizic acid preparations.METHODS:A total of 195 patients with tuberculosis admitted into the Tuberculosis Department of the Fifth People's Hospital of Wuxi from Jan.2019 to Apr.2025 were retrospectively selected and divided into the group A(treated with magnesium isoglycyrrhizinate,69 cases),group B(treated with glycyrrhizin ammonium cysteine,63 cases)and group C(treated with compound ammonium glycyrrhizin S,63 cases)according to the hepatoprotective regimens,pharmacoeconomic evaluation was conducted by using cost-effectiveness analysis and incremental cost-effectiveness comparison analysis,and the sensitive analysis was performed.RESULTS:The overall effective rates of hepatoprotective treatment were respectively 89.86％(62/69),76.19％(48/63)and 71.43％(45/63)in group A,group B and group C.The cost-effectiveness ratios for the treatment regimens were respectively 6 442.03,7 603.26 and 7 891.54 in group A,group B and group C.According to the incremental cost-effectiveness ratios of the three hepatoprotective regimens,group A was the most economical,and the results of sensitivity analysis were consistent with the above findings.CONCLUSIONS:In the treatment of anti-tuberculosis drug induced liver injury,magnesium isoglycyrrhizinate demonstrates superior efficacy and cost-effectiveness compared with glycyrrhizin ammonium cysteine and compound ammonium glycyrrhizin S.